A lower dose regimen for cephradine capsules in the treatment of urinary tract infections.
In this double-blind, randomized, multicenter trial, an oral dosing regimen of 500 mg twice daily (BID) of cephradine was evaluated for the treatment of acute uncomplicated urinary tract infections due to susceptible pathogens. This dose was compared to the already established cephradine regimen of 1,000 mg BID. Of the 218 cases entered into the study, 130 were evaluable for efficacy, 64 in the 500-mg BID group and 66 in the 1,000-mg BID group. There was no statistically significant difference between the two dosage regimens regarding rapidity of clinical improvement, eradication of the pathogens, and overall therapeutic outcome. Successful responses were obtained in 89.1% of the 500-mg BID cases and in 87.9% of the 1,000-mg BID cases. These results demonstrate the safety and efficacy of a 500-mg BID dosing regimen of cephradine for this use. This regimen offers the advantages of convenience, potentially improved compliance, and cost economy.